Nucleai Secured $6.5M Series-A Initial Closing Led by Debiopharm To Advance AI-Powered Precision Oncology Platform - Nucleai, a computational biology company providing an AI-powered precision oncology platform for research and treatment decisions, secured $6.5M Series A initial closing. - Debiopharm's strategic corporate venture capital fund led the round joined by existing investors: Vertex Ventures and Grove Ventures.